Bausch Health Companies Inc. (BHC): Price and Financial Metrics


Bausch Health Companies Inc. (BHC): $29.31

-0.48 (-1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BHC POWR Grades


  • BHC scores best on the Growth dimension, with a Growth rank ahead of 98.25% of US stocks.
  • The strongest trend for BHC is in Stability, which has been heading up over the past 31 weeks.
  • BHC ranks lowest in Momentum; there it ranks in the 11th percentile.

BHC Stock Summary

  • Bausch Health Companies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 0.44% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 88.89 for Bausch Health Companies Inc; that's greater than it is for 99.49% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Bausch Health Companies Inc is reporting a growth rate of -153.08%; that's higher than just 13.69% of US stocks.
  • Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are WU, USDP, DXLG, HYMC, and TRIB.
  • Visit BHC's SEC page to see the company's official filings. To visit the company's web site, go to www.bauschhealth.com.

BHC Stock Price Chart Interactive Chart >

Price chart for BHC

BHC Price/Volume Stats

Current price $29.31 52-week high $34.80
Prev. close $29.79 52-week low $14.86
Day low $28.97 Volume 3,537,500
Day high $29.54 Avg. volume 3,996,841
50-day MA $30.33 Dividend yield N/A
200-day MA $24.88 Market Cap 10.50B

Bausch Health Companies Inc. (BHC) Company Bio


Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.

BHC Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$29.31$4.04 -87%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Bausch Health Companies Inc. To summarize, we found that Bausch Health Companies Inc ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 87%. As for the metrics that stood out in our discounted cash flow analysis of Bausch Health Companies Inc, consider:

  • In the past 5.77 years, Bausch Health Companies Inc has a compound free cash flow growth rate of -0.11%; that's better than only 13.18% of cash flow producing equities in the Healthcare sector, where it is classified.
  • 32% of the company's capital comes from equity, which is greater than just 6.27% of stocks in our cash flow based forecasting set.
  • Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.1. This coverage rate is greater than that of only 23.63% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-87%
1%-87%
2%-87%
3%-87%
4%-87%
5%-87%

Want more companies with a valuation profile/forecast similar to that of Bausch Health Companies Inc? See ALPN, CNMD, SKVI, ZBH, and ABC.


BHC Latest News Stream


Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream


Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.

11 Biggest Stock Scams In Recent Years

In this article we are going to list the 15 Biggest Stock Scams In Recent Years. Click to skip ahead and jump to the 5 Biggest Stock Scams In Recent Years. Money doesn’t bring happiness is a fine saying, but only if you have enough money not to have to worry about basic things. Ask a person […]

Yahoo | June 10, 2021

Global Plastic Surgery Devices Market 2021:Size, Industry Status and Growth opportunities,Competitive Outlook,Forecast To 2028||ADODERM GmbH, Bioha Laboratories, Surgisil LLP, Solta Medical (A Subsidiary of Bausch Health Companies Inc.), B. Braun Melsunge

Global plastic surgery devices market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.1% in the forecast period of 2021

OpenPR | June 8, 2021

Bausch + Lomb Signs Deal With Lochan to Develop New eyeTELLIGENCE Clinical Decision Support Software

Bausch + Lomb, a global eye health business owned by Bausch Health Companies Inc. (BHC), announced Tuesday that it has signed a deal with Lochan LLC. The post Bausch + Lomb Signs Deal With Lochan to Develop New eyeTELLIGENCE Clinical Decision Support Software appeared first on Smarter Analyst .

Smarter Analyst | June 8, 2021

Bausch + Lomb Signs Deal With Lochan to Develop New eyeTELLIGENCE™ Clinical Decision Support Software

Bausch + Lomb, a global eye health business owned by Bausch Health Companies Inc. (BHC), announced Tuesday that it has signed a deal with Lochan LLC. This software development company brings new solutions to complex ophthalmic calculations using artificial intelligence and advanced analytics. Under the agreement, the two companies will collaborate to develop the next generation of Bausch + Lomb eyeTELLIGENCE™ clinical decision support software. They plan to launch the first phase of the software

Yahoo | June 8, 2021

Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its affiliate has entered into an agreement with Lochan LLC ("Lochan") to develop the next-generation of Bausch + Lomb's eyeTELLIGENCE™ clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed to allow surgeons to seamlessly integrate all aspects of the cataract, retinal an

Yahoo | June 8, 2021

Read More 'BHC' Stories Here

BHC Price Returns

1-mo -7.10%
3-mo -11.18%
6-mo 41.66%
1-year 49.69%
3-year 18.95%
5-year 30.15%
YTD 40.91%
2020 -30.48%
2019 61.99%
2018 -11.12%
2017 43.11%
2016 -85.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0594 seconds.